ProCE Banner Activity

AE Management With TROP-2 ADCs in NSCLC


Download this slideset from a live symposium at ELCC 2024 for an expert overview of the adverse event profiles associated with the TROP-2 ADCs datopotamab deruxtecan and sacituzumab govitecan in advanced NSCLC, including similarities and differences along with guidance on their management.

Released: March 19, 2024



Luis Paz-Ares

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.